The 86 references in paper E. Shilov M., I. Bobkova N., I. Kolina B., E. Kamishova S., Е. Шилов М., И. Бобкова Н., И. Колина Б., Е. Камышова С. (2015) “КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ IgA-НЕФРОПАТИИ // CLINICAL RECOMMENDATIONS FOR DIAGNOSTICS AND TREATMENT OF IgA-NEPHROPATHY” / spz:neicon:nefr:y:2015:i:6:p:83-92

1
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Сhapter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2012;2: S209-S217
(check this in PDF content)
2
Мухин НА, Козловская ЛВ, Шилов ЕМ и др. Рациональная фармакотерапия в нефрологии. Рук. для практикующих врачей. Литерра, М., 2006; 896 с
(check this in PDF content)
3
Li PK, Ho KK, Szeto CC et al. Prognostic indicators of IgA nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial Transplant 2002; 17: 64–69
(check this in PDF content)
4
Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006; 69:1455–1458
(check this in PDF content)
5
Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-165
(check this in PDF content)
6
Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4: 943–946
(check this in PDF content)
7
Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286–2294
(check this in PDF content)
8
Jennette JC, Wall SD, Wilkman AS. Low incidence of IgA nephropathy in blacks. Kidney Int 1985; 28:944-950
(check this in PDF content)
9
D’Amico G, Colasanti G, Barbiano di Belgioioso G et al. Long-term follow-up of IgA mesangial nephropathy: clinicohistological study in 374 patients. Semin Nephrol 1987; 7: 355-358
(check this in PDF content)
10
Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994; 73: 79-102
(check this in PDF content)
11
Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6: 2535-2542
(check this in PDF content)
12
Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 2013; 28:
(check this in PDF content)
13
5-1314 13. Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795-1803
(check this in PDF content)
14
Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 2012; 34: 365-382
(check this in PDF content)
15
Boyd JK, Cheung CK, Molyneux K et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012; 81: 833-843
(check this in PDF content)
16
Gharavi AG, Yan Y, Scolari F et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354–357
(check this in PDF content)
17
Bisceglia L, Cerullo G, Forabosco P. et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79: 1130–1134
(check this in PDF content)
18
http://www.uptodate.com/contents/treatment-andprognosis-of-iga-nephropathy?source=related_link
(check this in PDF content)
19
Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110: 434-437
(check this in PDF content)
20
Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748
(check this in PDF content)
21
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402-2414
(check this in PDF content)
22
Habib R, Niaudet P, Levy M. Schцnlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher C, Brenner BM, eds. Renal pathology. Philadelphia: J.B. Lippincott, 1994: 472-523
(check this in PDF content)
23
D’Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-323
(check this in PDF content)
24
Berthoux F, Mohey H, Laurent B et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22: 752-761
(check this in PDF content)
25
Wakai K, Kawamura T, Endoh M et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006; 21: 2800-2808
(check this in PDF content)
26
Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512
(check this in PDF content)
27
Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735
(check this in PDF content)
28
Ikee R, Kobayashi S, Saigusa T et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res 2006; 29: 15-22
(check this in PDF content)
29
Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent endstage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203
(check this in PDF content)
30
Le W, Liang S, Hu Y et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012; 27: 1479-1485
(check this in PDF content)
31
Maixnerova D, Bauerova L, Skibova J et al. The retrospective analysis of 343 Czech patients with IgA nephropathy-one centre experience. Nephrol Dial Transplant 2012; 27: 1492-1498
(check this in PDF content)
32
Harden PN, Geddes C, Rowe PA et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-1542
(check this in PDF content)
33
Hunley TE, Julian BA, Phillips JA. 3rd. et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49: 571-577
(check this in PDF content)
34
Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727
(check this in PDF content)
35
Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA 48. nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
(check this in PDF content)
36
Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313-324
(check this in PDF content)
37
Daniel L, Saingra Y, Giorgi R et al. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000; 35: 13-20.
(check this in PDF content)
38
Weber CL, Rose CL, Magil AB. Focal segmental glomerulosclerosis in mild IgA nephropathy: a clinical-pathologic study. Nephrol Dial Transplant 2009; 24: 483-488
(check this in PDF content)
39
Lee HS, Lee MS, Lee SM et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant 2005; 20: 342-348
(check this in PDF content)
40
Manno C, Strippoli GF, D’Altri C et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis 2007; 49: 763-775
(check this in PDF content)
41
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545
(check this in PDF content)
42
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556
(check this in PDF content)
43
Reid S, Cawthon PM, Craig JC et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; CD003962
(check this in PDF content)
44
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48
(check this in PDF content)
45
Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54: 360-365
(check this in PDF content)
46
Praga M, Gutiérrez E, González E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
(check this in PDF content)
47
Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760
(check this in PDF content)
48
Coppo R, Peruzzi L, Amore A et al. IgACE: a placebocontrolled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888
(check this in PDF content)
49
Cattran DC. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol 2007; 18: 1633-1634
(check this in PDF content)
50
Li PK, Kwan BC, Chow KM et al. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 2013; 126: 162-168
(check this in PDF content)
51
Catapano F, Chiodini P, De Nicola L et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485
(check this in PDF content)
52
Donadio JV Jr, Bergstralh EJ, Offord KP et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199
(check this in PDF content)
53
Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12: 791-799
(check this in PDF content)
54
Ferraro PM, Ferraccioli GF, Gambaro G et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009; 24: 156-160
(check this in PDF content)
55
Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18: 354-361
(check this in PDF content)
56
Locatelli F, Del Vecchio L, Pozzi C. The patient with IgA glomerulonephritis-what is the role of steroid treatment? Nephrol Dial Transplant 1999; 14: 1057-1060
(check this in PDF content)
57
Lv J, Xu D, Perkovic V et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 1108-1114
(check this in PDF content)
58
Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
(check this in PDF content)
59
Manno C, Torres DD, Rossini M. et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701
(check this in PDF content)
60
Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180
(check this in PDF content)
61
Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 1983; 20: 172-176
(check this in PDF content)
62
Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14: 361-364
(check this in PDF content)
63
Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103-107
(check this in PDF content)
64
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
(check this in PDF content)
65
Yoshikawa N, Honda M, Iijima K et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 511-517
(check this in PDF content)
66
Pozzi C, Andrulli S, Pani A et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21: 1783-1790
(check this in PDF content)
67
Floege J, Eitner F. Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol 2010; 21: 1604-1606
(check this in PDF content)
68
Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22: 1785-1794
(check this in PDF content)
69
Kamei K, Nakanishi K, Ito S. et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 1301-1307
(check this in PDF content)
70
Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int 2004; 65: 1842-1849
(check this in PDF content)
71
Tang SC, Tang AW, Wong SS et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77: 543-549
(check this in PDF content)
72
Dal Canton A, Amore A, Barbano G et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol 2005; 18: 136-140
(check this in PDF content)
73
Lai KN, Lai FM, Li PK, Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J (Clin Res Ed) 1987; 295: 1165-1168
(check this in PDF content)
74
Kim YC, Chin HJ, Koo HS, Kim S. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS One 2013; 8: e71545
(check this in PDF content)
75
Welch TR, McAdams AJ, Berry A. Rapidly progressive IgA nephropathy. Am J Dis Child 1988; 142: 789-793
(check this in PDF content)
76
Lai KN, Lai FM, Leung AC et al. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am J Kidney Dis 1987; 10: 66-70
(check this in PDF content)
77
Roccatello D, Ferro M, Coppo R et al. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995; 10: 2054-2059
(check this in PDF content)
78
McIntyre CW, Fluck RJ, Lambie SH. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001; 56: 193-198
(check this in PDF content)
79
Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-1329
(check this in PDF content)
80
Xie Y, Nishi S, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867
(check this in PDF content)
81
Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51: 147-152
(check this in PDF content)
82
Kawamura T, Yoshimura M, Miyazaki Y et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014; 29: 1546-1553
(check this in PDF content)
83
Zand L, Fervenza FC. Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy? Nephrol Dial Transplant 2014; 29:1456-1459
(check this in PDF content)
84
Wang Y, Chen J, Wang Y et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 1923-1931
(check this in PDF content)
85
Ferri C, Puccini R, Longombardo G. et al. Low-antigencontent diet in the treatment of patients with IgA nephropathy. Nephrol Dial Transplant 1993; 8: 1193-1198
(check this in PDF content)
86
Coppo R, Roccatello D, Amore A et al. Effects of a glutenfree diet in primary IgA nephropathy. Clin Nephrol 1990; 33: 72-86 Авторы заявляют об отсутствии конфликта интересов. Поступила в редакцию: 30.04.2015 г.
(check this in PDF content)